Finance

Lists
Why is KLRS down ५.६०%?
Dive Deeper
KLRS:NASDAQ
Kalaris Therapeutics Inc
US$ २.३६
-५.६०%
(-०.१४) 1D
US$ २.४०
+१.६९% (+०.०४०)
After hours
Closed: अक्टोबर ९, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KLRS...
Open
US$ २.४६
High
US$ २.५५
Low
US$ २.३६
Mkt. cap
५.६२ करोड
Avg. vol.
७४.९३ हजार
Volume
१.०४ लाख
52-wk high
US$ ११.८८
52-wk low
US$ २.३५
EPS
-US$ २.०९
Beta
०.४२
Shares outstanding
२.३८ करोड
No. of employees
२०
Open
US$ २.४६
High
US$ २.५५
Low
US$ २.३६
Mkt. cap
५.६२ करोड
Avg. vol.
७४.९३ हजार
Volume
१.०४ लाख
52-wk high
US$ ११.८८
52-wk low
US$ २.३५
EPS
-US$ २.०९
Beta
०.४२
Shares outstanding
२.३८ करोड
No. of employees
२०
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
६ मिनेट पहिले
Nasdaq (NDAQ) Stock May Trade Above Fair Value After A 97% Gain
MarketWatch
MarketWatch
·
१ घण्टा पहिले
S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index
ChartMill
ChartMill
·
१ घण्टा पहिले
XPEL (NASDAQ:XPEL): A GARP Stock with Profitable Growth and Reasonable Valuation
Seeking Alpha
Seeking Alpha
·
३ घण्टा पहिले
S&P 500 Index Concentration - Room At The Top
About Kalaris Therapeutics Inc
CEO-
Employees२०
Founded२०१९
HeadquartersBerkeley Heights, न्यु जर्सी, संयुक्त राज्य अमेरिका
Sector-
Websitekalaristx.com
Analyst ratings
Based on 3 analysts giving stock ratings to KLRS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for KLRS in the last 3 months.
Highest
Current US$ २.३६
US$ १७.०० (+६२०.३४%)
Average
US$ १५.५० (+५५६.७८%)
Lowest
US$ १४.०० (+४९३.२२%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Buy
Reiterated
US$ १४.००
+४९३.२%
08/12/2026
Yun Zhong
Wedbush
Buy
Reiterated
US$ १७.००
+६२०.३%
08/11/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/11/2026
Tara Bancroft
TD Cowen
Buy
Initiated
-
-
06/15/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
US$ २५.००
+९५९.३%
05/13/2026
Biren Amin
Piper Sandler
Hold
Maintained
US$ ७.००
+१९६.६%
03/30/2026
Daniil Gataulin
Chardan Capital
Buy
Initiated
US$ १९.००
+७०५.१%
12/23/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
९१.२६ लाख
७१.५७ लाख
७५.७२ लाख
९०.१८ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३६.१५ लाख
३६.४४ लाख
४२.६१ लाख
३३.६८ लाख
Operating expense
१.२७ करोड
१.०८ करोड
१.१८ करोड
१.२४ करोड
Total operating expenses
१.२७ करोड
१.०८ करोड
१.१८ करोड
१.२४ करोड
Operating income
-१.२७ करोड
-१.०८ करोड
-१.१८ करोड
-१.२४ करोड
Other non operating income
८.४७ लाख
८.०३ लाख
९.७७ लाख
८.७१ लाख
EBT including unusual items
-१.१९ करोड
-९९.९८ लाख
-१.०९ करोड
-१.१५ करोड
EBT excluding unusual items
-१.१९ करोड
-९९.९८ लाख
-१.०९ करोड
-१.१५ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.१९ करोड
-९९.९८ लाख
-१.०९ करोड
-१.१५ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.६४
-०.४४
-०.४६
-०.४८
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.२७ करोड
-१.०८ करोड
-१.१८ करोड
-१.२४ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू